Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

Mehmet Turgut; Mark Grey; Surbhi Sidana; Paula Rodríguez‐Otero; Joaquín Martínez‐López; Hamza Hashmi; Robin Carson; Rachel Kobos; Weili Sun; Kristen Lantz; Anne Seifert; Deborah Briseno-Toomey; Lisa O’Rourke; Ingrid Maria Cecilia Rubin; Diego Vieyra; Lijuan Kang; María‐Victoria Mateos; Luciano J. Costa; Nizar J. Bahlis; Aurore Perrot; Ajay K. Nooka; Jin Lu; Charlotte Pawlyn; Roberto Mina; Gastón Caeiro; Alain Kentos; Vânia Hungria; Donna Reece; Ting Niu; Anne K. Mylin; Charlotte T. Hansen; Raphael Teipel; Britta Besemer; Meletios Α. Dimopoulos; Elena Zamagni; Satoshi Yoshihara; Kihyun Kım; Chang Ki Min; Paul A. F. Geerts; Elena van Leeuwen-Segarceanu; Agata Tyczyńska; Juan Luis Reguera; Magnus Johansson; Markus Hansson

doi:10.1056/nejmoa2514663

Abstract

In patients with multiple myeloma who had received one to three previous lines of therapy, those in the teclistamab-daratumumab group had significantly longer progression-free survival than those in the DPd or DVd group. (Funded by Johnson & Johnson; ClinicalTrials.gov number, NCT05083169.).

Affiliated Institutions

Related Publications

Niraparib in Patients with Newly Diagnosed Advanced Ovarian Cancer

Antonio González-Martı́n , Bhavana Pothuri , Ignace Vergote +27 more

Among patients with newly diagnosed advanced ovarian cancer who had a response to platinum-based chemotherapy, those who received niraparib had significantly longer progression-...

2019 New England Journal of Medicine 2062 citations

Gilteritinib or Chemotherapy for Relapsed or Refractory <i>FLT3</i> -Mutated AML

Alexander E. Perl , Giovanni Martinelli , Jorge E. Cortés +28 more

Gilteritinib resulted in significantly longer survival and higher percentages of patients with remission than salvage chemotherapy among patients with relapsed or refractory <i>...

2019 New England Journal of Medicine 1122 citations

Avelumab plus Axitinib versus Sunitinib for Advanced Renal-Cell Carcinoma

Robert J. Motzer , Konstantin Penkov , John B.A.G. Haanen +25 more

Progression-free survival was significantly longer with avelumab plus axitinib than with sunitinib among patients who received these agents as first-line treatment for advanced ...

2019 New England Journal of Medicine 2439 citations

Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer

Ronan J. Kelly , Jaffer A. Ajani , Jarosław Kużdżał +24 more

Among patients with resected esophageal or gastroesophageal junction cancer who had received neoadjuvant chemoradiotherapy, disease-free survival was significantly longer among ...

2021 New England Journal of Medicine 1584 citations

Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma

Michael A. Postow , Jason Chesney , Anna C. Pavlick +18 more

The objective-response rate and the progression-free survival among patients with advanced melanoma who had not previously received treatment were significantly greater with niv...

2015 New England Journal of Medicine 2716 citations

Publication Info

Year: 2025
Type: article
Citations: 0
Access: Closed

External Links

View on DOI.org

Social Impact

Altmetric

Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma

PlumX Metrics

Social media, news, blog, policy document mentions

Citation Metrics

OpenAlex

Cite This

APA Style

                            
                                    Mehmet Turgut, 
                                
                                    Mark Grey, 
                                
                                    Surbhi Sidana
                                
                                et al.
                            
                            (2025). 
                            Teclistamab plus Daratumumab in Relapsed or Refractory Multiple Myeloma. 
                            New England Journal of Medicine
                            
                            .
                            https://doi.org/10.1056/nejmoa2514663

Identifiers

DOI: 10.1056/nejmoa2514663